News
KPTI
0.6300
+2.17%
0.0134
Karyopharm Therapeutics Q4 2024 Earnings Preview
Seeking Alpha · 8h ago
Karyopharm Therapeutics Inc <KPTI.OQ> expected to post a loss of 26 cents a share - Earnings Preview
Reuters · 1d ago
Weekly Report: what happened at KPTI last week (0210-0214)?
Weekly Report · 1d ago
Analysts Estimate Indivior PLC (INDV) to Report a Decline in Earnings: What to Look Out for
NASDAQ · 5d ago
Karyopharm Therapeutics Price Target Maintained With a $3.00/Share by RBC Capital
Dow Jones · 02/10 16:38
RBC Capital Reiterates Outperform on Karyopharm Therapeutics, Maintains $3 Price Target
Benzinga · 02/10 16:28
RBC Capital Sticks to Their Buy Rating for Karyopharm Therapeutics (KPTI)
TipRanks · 02/10 11:39
Weekly Report: what happened at KPTI last week (0203-0207)?
Weekly Report · 02/10 09:06
KARYOPHARM THERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 02/03 21:05
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Barchart · 02/03 15:05
Weekly Report: what happened at KPTI last week (0127-0131)?
Weekly Report · 02/03 09:06
Karyopharm Announces Executive Retention Equity Awards
TipRanks · 01/31 21:31
Piper Sandler Issues a Buy Rating on Karyopharm Therapeutics (KPTI)
TipRanks · 01/27 12:07
Weekly Report: what happened at KPTI last week (0120-0124)?
Weekly Report · 01/27 09:06
Verve Therapeutics (VERV) Moves 18.7% Higher: Will This Strength Last?
NASDAQ · 01/23 14:31
Weekly Report: what happened at KPTI last week (0113-0117)?
Weekly Report · 01/20 09:06
Karyopharm Therapeutics Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
Dow Jones · 01/15 12:01
HC Wainwright & Co. Reiterates Buy on Karyopharm Therapeutics, Maintains $7 Price Target
Benzinga · 01/15 11:53
Edward White Recommends ‘Buy’ on Karyopharm Therapeutics Amid Promising Outlook and Strategic Developments
TipRanks · 01/15 11:26
Piper Sandler Sticks to Their Buy Rating for Karyopharm Therapeutics (KPTI)
TipRanks · 01/14 11:57
More
Webull provides a variety of real-time KPTI stock news. You can receive the latest news about Karyopharm Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About KPTI
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, oral SINE compound that, like selinexor, selectively blocks the nuclear export protein XPO1.